Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.39 |
| ▸ | TET3 | O43151 | 4/20 | 0.39 |
| ▸ | FBXL19 | Q6PCT2 | 4/20 | 0.39 |
| ▸ | CXXC5 | Q7LFL8 | 4/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.39 |
| ▸ | CXXC4 | Q9H2H0 | 4/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.39 |
| ▸ | TET1 | Q8NFU7 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 2/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15547985 | 0.72 | KMT2A (0.45) | KMT2ATET3FBXL19CXXC5KDM2B | |
| SCHEMBL3931269 | 0.70 | KMT2A (0.71) | KMT2ATET3FBXL19CXXC5KDM2B | |
| SCHEMBL5136787 | 0.70 | KMT2A (0.40) | KMT2ATET3FBXL19CXXC5KDM2B | |
| SCHEMBL20510231 | 0.70 | PKLR (0.40) | KMT2ATET3FBXL19CXXC5KDM2B | |
| SCHEMBL30341801 | 0.70 | PKLR (0.40) | KMT2ATET3FBXL19CXXC5KDM2B | |
| SCHEMBL2331200 | 0.69 | MALT1 (0.42) | KMT2AMEN1TRPV1ALDH1A1 | |
| SCHEMBL1303878 | 0.69 | POLB (0.49) | KMT2AMEN1TSHRSMN1; SMN2 | |
| SCHEMBL5732611 | 0.68 | PKLR (0.51) | KMT2ACHRM2MEN1TRPV1LMNA | |
| SCHEMBL23779147 | 0.67 | KMT2A (0.69) | KMT2ATET3FBXL19CXXC5KDM2B | |
| SCHEMBL31446209 | 0.66 | AKR1C1 (0.34) | KMT2ACYP2C19MEN1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329700-B2 | Pyrazine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120277209-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2364308-B1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-8247418-B2 | Pyrazine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8053438-B2 | Pyrazine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20110160202-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160182-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160182-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | KMT2A 3603/4885TET3 2396/4885FBXL19 4187/4885 |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | KMT2A 3603/4885TET3 2396/4885FBXL19 4187/4885 |
| US-20110160202-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | KMT2A 3603/4885TET3 2396/4885FBXL19 4187/4885 |
| US-20120277209-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | KMT2A 3681/4885TET3 2353/4885FBXL19 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.